These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2157773)

  • 1. Effect of continuous administration of interferon-gamma in experimental visceral leishmaniasis.
    Murray HW
    J Infect Dis; 1990 May; 161(5):992-4. PubMed ID: 2157773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunochemotherapy for intracellular Leishmania donovani infection: gamma interferon plus pentavalent antimony.
    Murray HW; Berman JD; Wright SD
    J Infect Dis; 1988 May; 157(5):973-8. PubMed ID: 2834469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial response of a T cell-deficient host to cytokine therapy: effect of interferon-gamma in experimental visceral leishmaniasis in nude mice.
    Murray HW; Hariprashad J; Aguero B; Arakawa T; Yeganegi H
    J Infect Dis; 1995 May; 171(5):1309-16. PubMed ID: 7751708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
    Everlien H; Hockertz S
    Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of murine visceral leishmaniasis with murine recombinant interferon-gamma and MTP-PE encapsulated in liposomes.
    Hockertz S; Franke G; Paulini I; Lohmann-Matthes ML
    J Interferon Res; 1991 Jun; 11(3):177-85. PubMed ID: 1919076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sub-optimal dose of Sodium Antimony Gluconate (SAG)-diperoxovanadate combination clears organ parasites from BALB/c mice infected with antimony resistant Leishmania donovani by expanding antileishmanial T-cell repertoire and increasing IFN-gamma to IL-10 ratio.
    Haldar AK; Banerjee S; Naskar K; Kalita D; Islam NS; Roy S
    Exp Parasitol; 2009 Jun; 122(2):145-54. PubMed ID: 19422069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo and in vitro antileishmanial activity of Bungarus caeruleus snake venom through alteration of immunomodulatory activity.
    Bhattacharya S; Ghosh P; De T; Gomes A; Gomes A; Dungdung SR
    Exp Parasitol; 2013 Sep; 135(1):126-33. PubMed ID: 23830987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma.
    Murray HW; Stern JJ; Welte K; Rubin BY; Carriero SM; Nathan CF
    J Immunol; 1987 Apr; 138(7):2290-7. PubMed ID: 3104456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental visceral leishmaniasis: role of trans-aconitic acid in combined chemotherapy.
    Kar S; Kar K; Bhattacharya PK; Ghosh DK
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2459-65. PubMed ID: 8285634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pentavalent antimony-mannan conjugate therapy of experimental visceral leishmaniasis.
    Roberts WL; Hariprashad J; Rainey PM; Murray HW
    Am J Trop Med Hyg; 1996 Oct; 55(4):444-6. PubMed ID: 8916804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effect of interferon-gamma gene transfer in experimental visceral leishmaniasis.
    Taylor AP; Murray HW
    J Infect Dis; 1998 Sep; 178(3):908-11. PubMed ID: 9728571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis.
    Murray HW; Oca MJ; Granger AM; Schreiber RD
    J Clin Invest; 1989 Apr; 83(4):1253-7. PubMed ID: 2539396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of pentostam (sodium stibogluconate) against cutaneous leishmaniasis in mice treated with neutralizing anti-interferon-gamma antibody.
    Nabors GS; Farrell JP
    Am J Trop Med Hyg; 1995 Jul; 53(1):55-60. PubMed ID: 7625533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful therapy of lethal murine visceral leishmaniasis with cystatin involves up-regulation of nitric oxide and a favorable T cell response.
    Das L; Datta N; Bandyopadhyay S; Das PK
    J Immunol; 2001 Mar; 166(6):4020-8. PubMed ID: 11238649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asiaticoside induces tumour-necrosis-factor-α-mediated nitric oxide production to cure experimental visceral leishmaniasis caused by antimony-susceptible and -resistant Leishmania donovani strains.
    Bhaumik SK; Paul J; Naskar K; Karmakar S; De T
    J Antimicrob Chemother; 2012 Apr; 67(4):910-20. PubMed ID: 22258930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative evaluation of efficacy of chemotherapy, immunotherapy and immunochemotherapy in visceral leishmaniasis-an experimental study.
    Joshi J; Malla N; Kaur S
    Parasitol Int; 2014 Aug; 63(4):612-20. PubMed ID: 24747611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani.
    Carter KC; Mullen AB; Sundar S; Kenney RT
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3555-9. PubMed ID: 11709339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis.
    Murray HW; Moreira AL; Lu CM; DeVecchio JL; Matsuhashi M; Ma X; Heinzel FP
    J Infect Dis; 2003 Aug; 188(3):458-64. PubMed ID: 12870129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leishmania donovani: CD2 biased immune response skews the SAG mediated therapy for a predominant Th1 response in experimental infection.
    Bimal S; Sinha S; Singh SK; Narayan S; Kumar V; Verma N; Ranjan A; Sinha PK; Das VN; Pandey K; Kar SK; Das P
    Exp Parasitol; 2012 Jul; 131(3):274-82. PubMed ID: 22580024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visceral leishmaniasis: resistance to reinfection in the liver following chemotherapy in the BALB/c mouse.
    Carter KC; Alexander J; Baillie AJ; Dolan TF
    Exp Parasitol; 1989 May; 68(4):375-81. PubMed ID: 2542078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.